"Prediction is very difficult, especially if it's about the future." Nils Bohr Leading pharmaceutical companies invest billions of dollars each year in research and development with little or no guarantee of a return on their investment. With the average cost of developing a new drug hitting the $800 million mark, accurately forecasting the market potential for new compounds is becoming an essential tool in long-term strategic planning. Forecasting is also essential in understanding how the dynamics of a market are changing, evaluating licensing and acquisition opportunities for a particular therapeutic candidate, and raising the awareness of company executives of both current and potential future competitors. Last, but not least, pharmaceutical product forecasting provides precious building blocks for modeling and simulation exercises that investment analysts need to conduct on a continuous bases to estimate return-on-investment decisions and fine tune their portfolios. Pharma Reports specializes in modeling and publishing short and medium term event-impacted linear forecasts for both new and established drugs. Since actual brand performance depends on how the marketing company allocates its resources and how the competition responds to changes in market shares, we revise our forecasts periodically as new data points become available.